<DOC>
	<DOCNO>NCT00743743</DOCNO>
	<brief_summary>Objective : To determine effect resveratrol extract give 215 mg dose daily supplement currently available counter , cognitive global functioning patient mild moderate AD standard therapy .</brief_summary>
	<brief_title>Pilot Study Effects Resveratrol Supplement Mild-to-moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Background : Many animal vitro study show resveratrol , naturally occur polyphenol find red wine , increase cognition , reduce neural degeneration , promote clearance amyloid-beta peptide , alter age mechanism . Therefore , resveratrol may reduce symptom Alzheimer 's disease ( AD ) possibly pathology . Objective : A pilot study determine effect resveratrol cognitive , behavioral global functioning patient mild-to-moderate AD standard therapy . Design : Randomized , double-blind , placebo-controlled clinical trial . Participants : 50 patient mild-moderate Alzheimer 's disease ( AD ) define Mini-Mental State Exam ( MMSE ) 10-27 enrolled study . Patients must establish diagnosis AD NINCDS diagnostic criterion , stable dose cognitive enhancing medication ( cholinesterase inhibitor and/or NMDA receptor antagonist ) Screening/Enrollment : Institutional Review Board approval obtain . The chart review enrollment discussion carry non-physician member research team . Participants screen randomized total 50 eligible patient , 25 arm obtain .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>Inclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Male female subject clinical diagnosis probable Alzheimer 's disease accordance NINCDSADRDA criterion ( Appendix 2 ) . 2 . Subject mild moderate Alzheimer 's disease define MMSE score 10 27 inclusive Screening . 3 . Hachinski Ischemia Score ≤ Screening ( See Appendix 3 ) . 4 . Age ≥50 ≤90 year . 5 . At least 6 month ongoing acetylcholinesterase inhibitor therapy Alzheimer 's disease , stable dose least last 2 month ( intent change duration study ) . 6 . Current use medication accordance criterion list Table 2 ( Permitted Medications , Section 8.1 ) . 7 . Female subject must postmenopausal ( i.e . &gt; 24 week without menstrual period ) , surgically sterile , agree use adequate method contraception duration study . Female subject premenopausal postmenopausal &lt; 2 year must undertake pregnancy test ( urine test ) Visit 1 , must negative . 8 . Brain CT MRI scan perform within past 12 month Screening , show evidence potential cause dementia Alzheimer 's disease . 9 . Neurological exam without focal change ( exclude change attributable AD peripheral trauma ) . 10 . Subject ability comply procedure cognitive test . 11 . Subject life ( substantial period contact ) regular caregiver willing attend visit , oversee subject 's compliance protocolspecified procedure study medication , report subject 's status . 12 . Subject provide full write informed consent prior performance protocolspecified procedure ; unable provide inform consent due cognitive status , full write informed consent behalf subject provide legally acceptable representative . 13 . Caregiver provide full write informed consent his/her behalf prior performance protocolspecified procedure . Exclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Diagnosis possible , probably , definite vascular dementia accordance NINDSAIREN criterion ( Appendix 4 ) . 2 . History evidence CNS disorder could interpret cause dementia ; e.g . cerebrovascular disease ( stroke , hemorrhage ) , structural abnormality , epilepsy , infectious inflammatory/demyelinating CNS condition , Parkinson 's disease . 3 . Evidence follow disorder : current vitamin B12 deficiency , positive syphilis serology , active thyroid dysfunction ( particularly suggestive hypothyroidism ) , include abnormally high low serum level thyroid stimulate hormone ( TSH ) clinically significant opinion investigator . 4 . History Type 1 diabetes mellitus secondary diabetes mellitus . 5 . Type 2 diabetes mellitus subject treated insulin , PPARγ agonist , insulin secretagogue ( e.g . sulfonylurea glitinide ) . 6 . Any patient HbA1c≥8.5 % . ( See Section 6.3.8.4 Safety Measures Enrolled Subjects Type 2 Diabetes Mellitus . ) 7 . History clinical/investigational evidence congestive heart failure define New York Heart Association criterion ( Class I IV cardiac status ; Appendix 5 ) . 8 . History cardiovascular event within last 6 month ( i.e . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ] significant arrhythmia ; major intervention ( e.g . cardiac surgery angiography plus stenting ) schedule ) . 9 . History significant psychiatric illness schizophrenia bipolar affective disorder opinion Investigator would interfere participation study , major depressive disorder ( accord DSMIV ) past year , current active depression require treatment . 10 . History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug , , clinically relevant abnormality , medical psychiatric condition , , opinion Investigator , make subject unsuitable inclusion study . 11 . Clinically significant peripheral edema time screen . 12 . Current recent drug alcohol abuse dependence ( define DSMIV criterion substancerelated disorder ) , recent remote history could contribute factor dementia . 13 . Systolic blood pressure &gt; 165 &lt; 90 mmHg diastolic blood pressure &gt; 95 &lt; 60 mmHg time screen . 14 . Clinically significant anemia ( i.e . hemoglobin &gt; 11 g/dL male &lt; 10 g/dL female ) presence hemoglobinopathy would prevent accurate assessment HbA1c . 15 . Abnormal kidney function test ( &gt; 1.5 time upper limit normal ( ULN ) ) . 16 . ALT , AST , alkaline phosphatase value &gt; 2.5 time ULN , total bilirubin value &gt; 1.5 time ULN , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) . 17 . History bone marrow transplant . 18 . Subject unable ( assistance , appropriate ) take study medication prescribe throughout study risk noncompliance study medication procedure . 19 . Subject immediate family member employee participate Investigator , participate site staff .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>dementia</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>cognition</keyword>
	<keyword>function</keyword>
	<keyword>behavior</keyword>
	<keyword>treatment</keyword>
</DOC>